Life Extension ArthroMax™ with Theaflavins & AprèsFlex™, 120 vege caps

 Life Extension ArthroMax™ with Theaflavins & AprèsFlex™, 120 vege caps QR Code
  • Item No: 001617
  • Availability: In Stock
  • S$84.70

  • Ex GST: S$79.16
    Pricing for shipping addresses out of Singapore

  • 10% off for 4 or more

Pre Order Form

We will keep you posted on stock status.

As you grow older, age-related stiffness and discomfort in the joints becomes a fact of life. Activities once routine become a challenge as limited mobility hampers your every move.

Inflammatory reactions are regulated by a series of "cytokines" produced in the body. Normal aging results in an unfavorable balance of these cytokines that contributes to persistent inflammatory conditions. Studies have shown that a special fraction found in black tea suppresses proinflammatory cytokines at the genomic level. Scientists have found that these com­pounds called theaflavins uniquely downregulate the expression of genes associated with inflammatory cytokines.72

ArthroMax® with Theaflavins & AprèsFlex® provides bioactive theaflavin fractions, along with MSM(methylsulfonylmethane), which contains sulfur components that are critically important in maintain­ing comfortable joint function.73-75 It also contains FruiteX B® OsteoBoron®, a patented form of boron identical to natural plant forms found in food. Considered more bioavail­able than other forms of boron, FruiteX B® OsteoBoron® also supports healthy bones and joints.76-78

AprèsFlex® represents a quantum leap forward in the delivery of boswellia to aging joints. Long prized for its ability to help inhibit inflammatory factors, boswellia is especially effective at inhibiting the 5-LOX (5-lipoxygenase) enzyme.

Excess activity of 5-LOX results in the accumulation of leukotriene B4, a pro-inflammatory compound that affects aging joints. Boswellia has been shown to bind directly to the 5-LOX enzyme, preventing it from facilitating production of pro-inflammatory leukotrienes.69,70

AprèsFlex® boswellia absorbs into the blood 52% better than previously available forms of boswellia, for superior effectiveness.71

Supplement Facts

Serving Size 4 vegetarian capsules

Servings Per Container 30

Amount Per Serving

Glucosamine sulfate 2KCI (derived from corn)

2000 mg

Methylsulfonylmethane (MSM)

1000 mg

Black tea theaflavins decaffeinated extract (leaf) [standardized to 12% TF2a fraction (52.8 mg), along with TF-1, TF2b and TF3 theaflavin fractions]

440 mg

AprèsFlex® Indian frankincense (Boswellia serrata) extract (gum resin) [std. to 20% 3-O-acetyl-11-keto-ß-boswellic acid (AKBA) (20 mg)]

100 mg

Boron (calcium fructoborate as patented FruiteX B® OsteoBoron®)

1.5 mg

Other ingredients: vegetable cellulose (capsule), microcrystalline cellulose, vegetable stearate, silica.

AprèsFlex® is a registered trademark of Laila Nutraceuticals exclusively licensed to PL Thomas – Laila Nutra LLC. U.S. Patent No. 8,551,496 and other patents pending. 
FruiteX B® and OsteoBoron® are registered trademarks of VDF FutureCeuticals, Inc. U.S. Patent No. 5,962,049.

Dosage and Use
  • Take four (4) capsules (two capsules in the morning and two capsules in the afternoon) with food, or as recommended by a healthcare practitioner.
Warnings
  • KEEP OUT OF REACH OF CHILDREN
  • DO NOT EXCEED RECOMMENDED DOSE
  • Do not purchase if outer seal is broken or damaged.
  • When using nutritional supplements, please consult with your physician if you are undergoing treatment for a medical condition or if you are pregnant or lactating.

References

1. Acta Obstet Gynecol Scand. 1993 Apr;72(3):148-56.
2. Rheum Dis Clin N Am 33 (2007) 149-176
3. Eur J Clin Invest. 1988 Oct;18(5):529-34. 
4. Bone. 2001 Mar;28(3):327-31.
5. Endocr Rev. 2011 Feb;32(1):31-63.
6. J Osteoporos. 2011;2011:108324. doi: 10.4061/2011/108324. Epub 2011 Nov 1.
7. J Endocrinol. 2002 Mar;172(3):673-81.
8. Gynecol Obstet Fertil. 2007 Sep;35(9):785-90.
9. J Prosthet Dent. 1995 Jan;73(1):65-72. 
10. Am J Clin Nutr. 2000 Sep;72(3):681-9.
11. Clin Calcium. 2006 Oct;16(10):1624-31. 
12. J Nutr Elder. 2008;27(1-2):3-27.
13. Calcif Tissue Int. 2011 Feb;88(2):117-29.
14. Clin Ter. 2009;160(2):105-9.
15. Sports Med. 2009;39(6):439-68.
16. J Am Geriatr Soc. 2005 Nov;53(11):1875-80.
17. J Clin Invest. 2006 Dec;116(12):3150-9.
18. Mol Cell Endocrinol. 2011 Dec 5;347(1-2):48-54.
19. Bone Miner. 1994 Dec;27(3):235-47.
20. Biorheology. 2002;39(1-2):237-46.
21. Drugs Aging. 2010 Feb 1;27(2):95-115 
22. Magnes Trace Elem. 1990;9(2):61-9.
23. Curr Pharm Des.2003;9(32):2687-704.
24. Ann Nutr Metab. 2002;46(6):249-53.
25. J Int Med Res. 2007 Sep-Oct;35(5):692-5.
26. J Nutr. 1994 Jul;124(7):1060-4.
27. Crit Rev Food Sci Nutr. 2006;46(8):621-8.
28. Magnes Res. 1993 Jun;6(2):155-63.
29. J Reprod Med. 1990 May;35(5):503-7.
30. J Clin Endocrinol Metab. 2010 Jun;95(6):2630-3.
31. Am J Clin Nutr. 1995 Mar;61(3 Suppl):638S-45S. 
32. Ann Nutr Metab. 2009;54(3):218-26  
33. Toxic Sci. 2006 Jul;92(1):286-94  
34. PDR for Nutritional Supplements, 1st ed. Montvale, NJ: Medical Economics Co.; 2001:288-95. 
35. J Nutr Sci Vitaminol (Tokyo). 1999 Oct;45(5):509-17. 
36. Methods Find Exp Clin Pharmacol. 1995 Sep;17(7):437-42.
37. Scand J Gastroenterol. 2010;45(2):133-8. 
38. Osteoporos Int. 2009 Jul;20(7):1175-82.  
39. Congest Heart Fail. 2006 Jan-Feb;12(1):9-13.
40. Br J Sports Med. 2006 Sep;40(9): 773-8. 
41. Front Biosci. 2004 May 1;9:1278-93. 
42. South Med J. 2001 Dec;94(12):1195-201. 
43. PDR for Nutritional Supplements, 1st ed. Montvale, NJ: Medical Economics Co.; 2001:60-3. 
44. Environ Health Perspect. 1994 Nov;102 Suppl 7:59-63. 
45. Bone. 2003 Feb;32(2):127-35.
46. Magnes Res. 1993 Sep;6(3):247-9.
47. Biol Trace Elem Res. 2009 Jun;128(3):239-47. 
48. Environ Health Perspect. 1994 Nov;102 Suppl 7:83-5.
49. Crit Rev Food Sci Nutr. 2003;43(2):219-31. 
50. Prog Food Nutr Sci. 1993 Oct-Dec;17(4):331-49. 
51. Nutr Rev. 2008 Apr;66(4):183-91.
52. J Bone Miner Metab. 2001;19(3):146-9.
53. Osteoporos Int. 2007 Jul;18(7):963-72., 
54. J Bone Miner Res. 2007 Apr;22(4):509-19.
55. Natural Vitamin K2 as Menaquinone-7. Monograph April 2006
56. Blood. 2007 Apr 15;109(8):3279-83.
57. Vitam Horm. 2008;78:393-416.
58. Curr Drug Saf. 2006 Jan;1(1):87-97. 
59. Prog Food Nutr Sci. 1992 Oct-Dec;16(4):307-43
60. Valensa. (Data on File.) 2011.
61. Altern Med Rev. 2010 Apr;15(1):84-6.
62. J Am Coll Nutr. 2007 Feb;26(1):39-48.
63. Curr Med Chem. 2009;16(14):1718-45.
64. Curr Rheumatol Rep. 2003 Feb;5(1):7-14.
65. Nutr J. 2008;7:3.
66. Am J Phys Med Rehabil. 2005 Apr;84(4):278-83; quiz 84, 93.
67. World J Gastroenterol. 2007 Feb 14;13(6):945-9.
68. J Nutr Biochem. 2010 May;21(5):381-9.
69. Wien Med Wochenschr. 2002;152(15-16):373-8. 
70. J Ethnopharmacol. 2006 Sep 19;107(2):249-53.
71. Mol Cell Biochem. 2011 Aug;354(1-2):189-97.
72. Mol Nutr Foods Res 2006 Feb;50(2):115-22.
73. Adv Ther. 2011 Oct;28(10):894-906. 
74. Acta Vet Scand. 2008 Nov 7;50:45. 
75. Nutr J. 2008 Oct 27;7:31. 
76. Miljkovic D (1999) Boron and carbohydrate complexes and uses thereof. U.S. Patent # 5,962,049. 
77. Miljkovic ND, Miljkovic DA, Ercegan GM (2002) Osteoarthritis and Calcium Fructoborate Supplementation: An Open-Label Study. FutureCeuticals Internal Study. 
78. Available at: http://www.futureceuticals.com/pdfs/r_d_section/fc_research_page/by_product/fruitex_b/5._fruitexb_increases_bone_density-r_d.pdf Accessed December 17, 2012.
79. Int J Med Sci. 2009;6(6):312-21.
80. Proc Natl Acad Sci U S A. 1986 Oct;83(19):7443-6.
81. Int Immunopharmacol. 2011 Jan;11(1):12-8.
82. Int J Clin Pharmacol Res. 2002;22(3-4):101-10.
83. Immunol Rev. 2005;206:232-59.
84. J Vet Pharmacol Ther. 2005 Aug;28(4):385-90.
85. J Vet Pharmacol Ther. 2007 Jun;30(3):275-8.
86. Toxicol Mech Methods. 2007;17(4):189-96.
87. J Anim Physiol Anim Nutr (Berl). Epub 2011 May 30.
88. J Vet Pharmacol Ther. 2009 Dec;32(6):577-84.
89. http://www.koact.net/index.php?id=science Accessed December 17, 2012.
90. BMJ. 2005 Jun 18;330(7505):1400-1.
91. J Clin Endocrinol Metab. 2005 May;90(5):2816-22.
92. Joint Bone Spine. 2004 Jul;71(4):261-3.
93. Int Immunopharmacol. 2009 Mar;9(3):313-8. 
94. Clin Rheumatol. 2009 Aug;28(8):931-463. 
95. Chandran B, Chakkiath VK, Thomas SPO. A multicentre, randomized, controlled human clinical study to assess the efficacy and safety of Biocurcumax (BCM-95®) compared to diclofenac sodium. Submitted for publication. 2009.
96. Indian J Pharm Sci. 2008 Jul-Aug;70(4):445-9.
97. http://www.docstoc.com/docs/57587485/Nutraceutical-Composition-Comprising-Soluble-Keratin-Or-Derivative-Thereof---Patent-7579317 accessed December 18, 2012.
98. Biol Pharm Bull. 2003 Sep;26(9):1283-8. 
99. Life Sci. 2003 Jun 13;73(4):471-85. 
100. Mol Pharmacol. 2006 Jun;69(6):1783-90. 
101. Mapo Pain Clinic, Seoul. November 2001. Scigenic Co., Ltd. Unpublished study report obtained from manufacturer. 
102. J Agric Food Chem. 2008 Nov 26;56(22):10582-93. 
103. Nutr J. 2008 Jan 21;7:3.
104. Curr Med Res Opin. 2008 May;24(5):1485-96.
105. Int J Food Sci Nutr. 2009;60 Suppl 2:99-113.
106. Am J Physiol Heart Circ Physiol. 2008 Mar;294(3):H1365-70.
107. Clin Immunol. 2008 Jul;128(1):66-74. Epub 2008 May 14.
108. Evid Based Complement Alternat Med. 2004 Dec;1(3):251-7.
109. Clin Exp Rheumatol. 2006 Jan-Feb;24(1):25-30.
110. Clin Rheumatol. 2004 Oct;23(5):410-5.
111. Arthritis Res Ther. 2007;9(6):R117. 
112. Evid Based Complement Alternat Med. 2007 Jun;4(2):219-24. 
113. N Engl J Med. 2006 Feb 23;354(8):795-808. 
114. Eksp Klin Farmakol. 2002 Nov-Dec;65(6):67-9. 
115. Fortschr Med. 1980 Jun 5;98(21):801-6. 
116. Osteoarthritis Cartilage. 2003 Jun;11(6):424-32. 
117. Osteoarthritis Cartilage. 1998 Nov;6(6):427-34. 
118. Rheumatol Int. 2007 Jan;27(3):213-8.  
119. Arthritis Rheum. 2007 Feb;56(2):555-67.

Write a review

Please login or register to review

Related Products

Tags: life, extension, arthromax™, with, theaflavins, aprèsflex™, 120, vege, caps, bone, joint